Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.
Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.
We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.
Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.
Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.
The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.
EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.
EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.
EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.
Bio-Prodict is focused on delivering solutions for guiding scientific research in the field of protein engineering, molecular design and DNA diagnostics. We apply novel approaches to data mining, storage and analysis of protein data and combine these with state-of-the art analysis methods and visualization tools to create custom-built information systems for protein superfamilies.
Over the years, these systems have proved to be powerful instruments for understanding many of the complex aspects involved in protein function and mutation effect prediction.
Years of experience in software design, structural biology and the analysis of protein super-family data make Bio-Prodict your choice for protein-related data analysis and software design.
Coris BioConcept is a leading expert in the field of immunochromatographic (IC) and oligochromatographic (OC) technologies. Based in Belgium and established in 1996 by Thierry Leclipteux (CEO), the company develops, produces and markets diagnostic kits, mainly for the detection of human respiratory and gastro-enteric infectious pathogens (bacteria, virus and parasites), and for the detection of antibiotic resistance markers (RESIST products). These rapid tests are extensively used in microbiology laboratories worldwide.
To complement this extensive range of fast and accurate lateral flow tests, the company has developed an innovative fully automated platform that performs multiplex PCR amplification and detection, on a microfluidic cartridge (TRAPIST products). This molecular
multiplex plateform allows syndromic diagnostic approach for the clinical management of main human infections like in sepsis, meningitidis, respiratory and enteric diseases.
Coris BioConcept is currently involved in multiple collaborative international projects (under Belgian and/or European grants) for the development of class-B metallo-betalactamase rapid IC tests, fast and unique nucleic acid extraction system from blood cultures, nanotechnology solution to fight against multi-drug resistant bacteria, and much more projects.
This R&D expertise is ideally suited for the “on-demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfill the CE marking requirements and the company is also certified ISO 1 3485.
Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years.
Domainex’s highly experienced molecular, protein, structural and assay biologists plus medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets.
Domainex offers a range of services including:
• Medicinal chemistry (including SBDD)
• FragmentBuilder (Domainex’s proprietary fragment screening platform)
• Computational Chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform)
• Assay Development and Screening (biochemical, biophysical and cell assays)
• iPSC and immune cell biology
• Protein Production
• CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains)
• Analytical chemistry
• X-ray crystallography services
Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.